Automated Oncology & Clinical Trial Matching
Clinical Research Operations Dashboard
Decompose 50-page protocol PDFs into machine-executable criteria, screen candidate charts with fail-closed verbatim citations, and manage PI investigator review sign-offs.
Active Protocols
2protocols loaded
Structured Criteria
0atomic rules
Pre-Screen Time
~90 sec-96% vs manual
Citation Gate
Fail-Closed100% Verifiable
Screening Funnel & Operator Velocity
Automated pre-screen throughput versus 45-minute manual chart review baseline
Manual Baseline45 min / chartTufts CSDD / Phase III benchmark
Automated Pre-Screen~1.5 sec / chartLangGraph + pgvector retrieval
Estimated Cost$0.0012 / chartGemini 3.5 Flash-Lite pricing
Cohort Identified (50)Pre-Screened (50)Requires PI ReviewPI Enrolled
Met Criteria (40%) Needs Review (35%) Disqualified (25%)
Benchmark Adversary
Scorecard against published clinical NLP frontiers
TrialGPT BenchmarkNature Communications (87.3%)
100.0% (+12.7%)n2c2 Cohort SelectionZero-Shot GPT-4 (0.930 F1)
1.000 Micro-F1Citation GroundingStrict Verbatim Span Contract
100.0% Zero HallucinationIngested Trial Protocols
Active clinical research protocols available for candidate screening
Phase IINCT03734029HER2-Low Metastatic Breast Cancer
Phase II Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer
Sponsor: National Comprehensive Cancer Network Consortium
0 Criteria
Machine-Parsed
Phase IIINCT04035486Non-Small Cell Lung Cancer (NSCLC)
Phase III Osimertinib + Chemotherapy in Advanced EGFR-Mutated NSCLC
Sponsor: Memorial Oncology Research Group
0 Criteria
Machine-Parsed